CD14+HLA-DRlow/- expression: A novel prognostic factor in chronic lymphocytic leukemia

Jinlin Liu; Yonglie Zhou; Qiang Huang; Liannv Qiu

doi:10.3892/ol.2014.2808

CD14⁺HLA-DR^low/- expression: A novel prognostic factor in chronic lymphocytic leukemia

Oncol Lett. 2015 Mar;9(3):1167-1172. doi: 10.3892/ol.2014.2808. Epub 2014 Dec 17.

Authors

Jinlin Liu¹, Yonglie Zhou¹, Qiang Huang², Liannv Qiu¹

Affiliations

¹ Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310004, P.R. China.
² Department of Hematology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310004, P.R. China.

Abstract

Currently, no prognostic factors exist for determining the host immune status of chronic lymphocytic leukemia (CLL) patients. Therefore, the present report analyzed cluster of differentiation 14 (CD14)⁺ human leukocyte antigen (HLA)-DR^low/- myeloid-derived suppressor cells (MDSC) from 49 CLL patients and demonstrated that these cells were significantly expanded in all CLL patients when compared with monoclonal B cell lymphocytosis patients and healthy volunteers. Furthermore, upregulation of CD14⁺HLA-DR^low/- MDSCs was correlated with CLL tumor progression and a poor prognosis for CLL patients, and CD14⁺HLA-DR^low/- MDSCs were significantly correlated with the presence of CD4⁺ T and CD5⁺CD19⁺ cells in CLL patients, which could significantly inhibit the CD4⁺ T-cell immune response, contributing to CLL cell progression in CLL patients.

Keywords: CD14+HLA-DRlow/−; chronic lymphocytic leukemia; prognostic factor.